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ABSTRACT 
The studies described in this thesis aimed to identify novel factors involved in the 
regulation of longitudinal growth and bone mineralization in response to growth 
hormone (GH) treatment.  
This was done by performing a single factor study (Paper I) where it was found that 
growth response was negatively correlated with adiponectin levels during the first year 
of GH treatment in short prepubertal children. Thereafter a genomic approach using 
microarray was used to identify GH and insulin-like growth factor I responsive genes 
in primary cultured human chondrocytes, from the growth plate, where GH has direct 
and indirect effects (Paper II). The COMP gene was found to be up-regulated by GH, 
which was confirmed using ELISA in short prepubertal children.  
In Papers III–V a pharmacoproteomic approach was used to identify novel GH-
regulated protein markers for longitudinal growth and bone mineralization. Serum 
protein expression profiles during the first year of GH treatment were analysed using 
SELDI-TOF in two different study groups. In Paper III changes in protein peak 
intensities allowed 82% of children to be correctly classified as good or poor 
responders. In Paper IV and V it was found that it was possible to predict the 2-year 
growth response and bone mineralization and by comparing the proteins in the 
regression models it was found that these are partly dissociated mechanisms. The 
proteins identified in Paper III-V were Apolipoprotein (Apo) A-I, Apo A-II, Apo C-I, 
Apo C-III, transthyretin, serum amyloid A4 and haemoglobin beta. All proteins 
except haemoglobin beta were related to the high-density lipoprotein. Robust 
statistical methods were used and developed to ensure valid proteomic data as well as 
reliable results.  
In conclusion: different techniques from ELISAs to genomics and proteomics were 
used to identify novel GH-dependent factors. Our results suggest that nutritional 
factors may have a role in determining GH responsiveness. In future, this knowledge 
could be useful in the development of tools for the diagnosis and individualized 
treatment of short children, independently of low GH secretion or low GH sensitivity. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Målet med de studier som ingår i denna avhandling var att finna nya 
tillväxthormonssreglerade faktorer som är av betydelse för längdtillväxt och 
benmineralisering hos barn. Det långsiktiga målet är att genom en ökad kunskap om 
vilka mekanismer som styr tillväxthormonets effekter i kroppen, kunna förbättra 
behandlingen av kortvuxna barn oavsett låg tillväxthormoninsöndring eller låg 
känslighet för tillväxthormon. Längdtillväxt är en komplex process som till stor del är 
beroende av ärftliga faktorer, hormonell reglering och nutrition. Kunskapen om de 
exakta mekanismer som styr denna process är idag begränsad.  
 
Inom ramen för projektet har olika tekniker använts för att studera biomarkörer i 
serumprover från kortvuxna barn. I första delarbetet studerades sambandet mellan 
adiponectin och tillväxt. Därefter studerades genuttrycket med hjälp av microarray 
teknik i primärodlade kondrocyter stimulerade med tillväxthormon och insulin-lik 
tillväxtfaktor. Resultaten verifierades i serumprover tagna vid start av tillväxthormon-
behandling och under behandling. I delarbete III-V användes den masspektrometri 
baserade tekniken SELDI-TOF för att studera proteinuttryck i serum. 
Vi fann att minskningen av adiponectin under första året av tillväxthormon-
behandling korrelerar med tillväxtsvaret. Nya tillväxthormon reglerade faktorer 
identifierades med microarray teknik, däribland cartilage oligomeric matrix protein 
(COMP). Proteiner för att separera hög- och lågsvarare på tillväxthormonbehandling 
och för att prediktera tillväxtsvar och benmineralisering hittades med 
proteomiktekniken SELDI-TOF. Även proteiner, som indikerar en dissociering 
mellan längdtillväxt och benmineralisering, hittades. Alla proteiner som hittades var 
relaterade till high-density lipoprotein (HDL), det ”goda” kolesterolet. 
 
Genom att kombinera traditionella analysmetoder med moderna avancerade genomik 
och proteomik tekniker har vi ökat kunskapen om tillväxthormonreglerade faktorer. 
Det kan på sikt göra det möjligt att förbättra såväl diagnostiken och kriterier för 
behandling och att anpassa behandlingen för den enskilde individen. 
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INTRODUCTION  
Growth in children is a complex process depending on the interplay between 
environmental factors, nutrition, various signalling systems, transcription factors and 
hormones such as, growth hormone (GH) and insulin-like growth factor I (IGF-I). 
GH is secreted by the pituitary and GH therapy promotes longitudinal growth in a 
dose-dependent way in short prepubertal children with GH deficiency (GHD), as well 
as in children with idiopathic short stature (ISS). In addition to promoting longitudinal 
growth in humans, GH has important metabolic functions including a role in bone 
mineralization, anabolism and lipolysis (102). Biomedical research has provided great 
insights into human growth, although much remains to be learned about the exact 
mechanisms of interaction and regulation of longitudinal growth (99, 162).  
A variety of different approaches have been used in attempts to identify novel factors 
involved in the regulation of longitudinal growth. Studies have looked at the impact of 
single factors and the simultaneous effects of multiple factors on growth (23, 24, 79). 
Investigations have included studies of genetic factors in families with inherited short 
stature (22, 28) and of biochemical factors such as adiponectin (167). Another 
approach has been to examine changes in gene expression in chondrocytes cultured 
with growth factors (23, 129). 
In the series of studies described here, the focus has been to study GH-mediated 
regulation of longitudinal growth and bone mineralization using a wide range of 
techniques. 
 
The first report of GH treatment in children was published in 1932 (51). This study, 
as well as later studies, supported the theory that pituitary extracts (including human 
GH) could enhance growth (113). In 1944, bovine GH was isolated from the pituitary 
(108) and in 1956 human GH was isolated (109). In 1979 the first recombinant human 
GH was produced, and in 1985, the first case of Creutzfeldt–Jakob disease was 
reported in a patient receiving pituitary-derived human GH (92). Following this 
finding, treatment with GH extracted from the human pituitary was stopped. In 1986 
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biosynthetic human GH became commercially available and research into its role in 
promoting growth subsequently intensified.  
 
Genetic factors are the primary determinant of adult height when nutrition, 
psychological well-being and levels of growth-related hormones are sufficient. GH is 
the major hormonal regulator of growth from about 9 months of age onwards (136). 
During childhood, juvenility and puberty, the longitudinal growth of a child is largely 
dependent on the amount of available endogenous GH. One cause of childhood 
growth failure is GHD. GHD during childhood is defined as a maximum GH 
response (GHmax) of less than 10 µg/L during an arginine–insulin tolerance test 
(AITT) and has been estimated to occur with an incidence of between 1 in 4000 and 1 
in 10 000 live births (114, 169). However, not all short children are GH-deficient 
regarding secretion. Some children may produce adequate levels of GH but have a 
poor response to GH at the target tissue level (94). 
 
The individual growth rate is dependent on the balance between the secreted level of 
biological active GH and target organ sensitivity, or responsiveness. Responsiveness 
to GH in the different tissues/target cells can be regulated, both at the receptor and 
the post-receptor level (55, 145). GH exerts its stimulatory effect on longitudinal 
growth in a dose-dependent way. This is achieved by direct stimulation of the growth 
plate (endocrine) (75, 76), and by stimulating the production of IGF-I by the liver 
(dual effector theory), which in turn stimulates the growth plate, as well as by 
stimulating local tissue production of IGF-I (paracrine and autocrine) (77, 78).  
The actions, half-life, and distribution of GH are modified by GH-binding proteins 
(GHBPs). These binding proteins may alter the distribution and biological activity of 
the different isoforms of GH (18, 112, 146). In addition to direct growth modulation 
by factors in the GH/IGF-I axis, several other hormones and locally produced factors 
are necessary for normal growth. Examples include thyroid hormone, insulin, sex 
steroids and signal substances from the immune system (42, 70, 181). In order to gain 
a better understanding of the complex system involved in the regulation of 
longitudinal growth and bone mineralization, there is a need to generate a clearer 
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picture of the underlying regulatory mechanisms. It is likely that a variety of factors 
contribute to the responsiveness of target tissues to GH.  
 
To identify novel factors that play a role in GH responsiveness a combination of 
genomics and proteomics can be used. However, when using genomic techniques like 
DNA microarrays, the measured mRNA levels do not always reflect the 
corresponding protein levels due to alternative splicing of mRNA, mRNA breakdown 
and post-transcriptional modifications of the proteins (19, 67). This has lead to an 
increasing interest in using proteomics, the large-scale analysis of the protein 
complement of the genome, the proteome. The main benefit of using proteomics, 
compared with mRNA-based methods, is that a proteomic approach identifies the 
actual active substances (i.e. proteins) in the biochemical processes studied. The main 
drawbacks are that proteomics is more complex than mRNA-based methods such as 
microarray as it is affected by different levels of regulation and the number of 
different proteins present in the samples. Both genomic and proteomic technologies 
rapidly generate large quantities of data. Processing of the data will lead to useful 
predictive mathematical descriptions of biological systems which will hopefully permit 
rapid identification of novel biomarkers and possibly lead to the identification of new 
therapeutic targets (19, 67). Furthermore, proteomics has the advantage that factors of 
interest can be measured in the blood, which is easily available.  
 
Bone physiology 
Bone is a dynamic adaptive tissue which has several important functions in the body 
including providing support for locomotion and protecting vulnerable internal organs. 
Bones are composed of calcium, phosphorus and other minerals, as well as the 
protein collagen. Calcium makes the bones hard and allows them to support body 
weight. The amounts of available vitamins and minerals, especially vitamin D and 
calcium, directly affect how much calcium is stored in the bones (59). Bone growth 
and bone development are highly dependent on other organs like the intestines and 
kidneys, through which mineral and nutritional factors are absorbed, reabsorbed and 
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excreted. In addition, the hypothalamus, pituitary, parathyroid glands, gonads and liver 
produce hormonal factors that are of importance for bone growth and stability (59). 
GH has both direct and indirect effects on bone growth via IGF-I (127). 
 
There are two main types of bone (Figure 1):  
Cortical bone (compact bone) is the solid outside part of the bone. Its main function is to 
support the body, protect the organs, provide leverage for movement, and store and 
release chemical elements (mainly calcium and phosphorous). Holes and channels 
carrying blood vessels and nerves run through the cortical bone (59). 
Trabecular bone (cancellous bone) is inside the compact bone. It is made up of a mesh-like 
network of tiny pieces of bone called trabeculae. The spaces in this network are filled 
with red marrow and yellow marrow. Red marrow is found mainly at the end of bones 
and is where most of the blood cells are made. Yellow marrow mostly consists of fat 
and is found throughout the bone (59). 
A large increase in bone mass occurs during childhood and puberty via endochondral 
bone formation (127). About half of the adult bone mass is developed during the 3–4 
years following the onset of puberty (59). A gradual increase in bone mass is then seen 
until peak bone mass is reached at 20–30 years of age (127).  
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Cortical bone
Trabecular bone 
Bone marrow
 
Figure 1. An overview of the bone showing the soft, spongy, trabecular bone and the hard cortical bone 
on the outside of the bones. 
 
The growth plate 
Children grow taller because their bones grow longer. The bones grow longer because 
they contain growth plates near the tip of both ends of the bone. The growth plate 
consists of cartilage within the epiphysis of the long bones. Within the growth plates, 
cells divide and enlarge, producing more cartilage which is subsequently converted 
into bone. This process causes the bones to elongate. The growth plate can be divided 
into several morphologically distinct zones (Figure 2).  
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 Germinal zone
Proliferative zone
Calcifying zone
Hypertrophic zone
 
Figure 2. Schematic illustration of the zones of the growth plate. Bone formation begins with 
mesenchymal cells in the germinal zone which condense and then start to differentiate into 
chondrocytes. Thereafter, the chondrocytes rapidly proliferate and mature to become hypertrophic. After 
further maturation, the calcification process begins. This is characterized by breakdown of the 
extracellular matrix, vascularization and infiltration of osteoclasts Thereafter, osteoblasts start to 
ossificate the free space created by the breakdown of the extracellular matrix by the osteoclasts and 
apoptosis of the chondrocytes (65, 104, 132). 
Chondrogenesis  
Numerous factors are involved during chondrogenesis and endochondral bone 
formation, many of them probably still unknown (99, 139). The different stages of 
chondrogenesis are shown in Figure 2 and summarized in Table 1.  
Chondrogenesis begins with the condensation of mesenchymal cells (Figure 2. 
Germinal zone). This process is characterized by a matrix rich in collagen (Col) type I, 
increased cell adhesion and the formation of gap junctions. At this stage, GH 
stimulates the prechondocytes to become chondrocytes, cartilage oligomeric matrix 
protein (COMP) is present and interacts with adhesion molecules to activate 
intracellular mechanisms that initiate the transition from chondroprogenitor cells to 
chondrocytes (58, 99). In the differentiation process of the chondroprogenitors, the 
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matrix is characterized by the expression of collagen II, IX, XI, aggrecan and COMP. 
At this stage some of the growth factors, IGF-I, fibroblast growth factors (FGFs) and 
bone morphogenetic proteins (BMPs) are controlling the differentiation process.  
Chondrocyte proliferation (Figure 2. Proliferative zone) is the process by which the 
number of chondrocytes rapidly increases. The major regulators of the rate of 
proliferation are the BMPs and FGFs, as well as the parathyroid hormone-related 
peptide (PRHrP)/Indian hedgehog (Ihh) systems together with IGF-I.  
Chondrocyte hypertrophy (Figure 2. Hypertrophic zone) is characterized by large 
increases in cell volume, the expression of the hypertrophic chondrocyte-specific 
marker type X collagen (Col10a1) and the expression of alkaline phosphatase. Another 
factor of importance is collagenase 3 (Table 2, Paper II), more commonly known as 
matrix metalloproteinase 13 (MMP-13). MMP-13 makes an important contribution to 
remodelling of the extracellular matrix (ECM), by degrading the ECM in the late 
hypertrophic zone. Remodelling of the ECM is considered to be a crucial step for 
angiogenesis and osteoblast recruitment during endochondral ossification.  
  
Table 1. Summary of the different stages of chondrogenesis. 
Process Characterized by 
Condensation Condensation of mesenchymal cells. GH is active 
Differention Expression of collagens and COMP, IGF-I has effect 
Proliferation Number of chondrocytes rapidly increases 
Hypertrophy Large increase in cell volume, collagen X expressed 
COMP, Cartilage oligomeric matrix protein; GH, Growth hormone; IGF-I, insulin-like growth factor 1. 
 
Growth in children 
Longitudinal growth can be divided into three different periods; infancy-childhood-
puberty (ICP) (88). The mainly nutrition dependent infancy growth is characterized by 
a gradual deceleration of growth and last for approximately 9 months (115) until the 
growth rate abruptly increases. This defines the start of the childhood growth phase. 
 17
  
During this phase the relationship between GH and growth is dose dependent and the 
growth is affected by the balance between GH secretion and tissue sensitivity (8, 41). 
After the start of puberty the growth is dependent also on other hormones, besides 
GH, like the sex hormones. 
In the northern and southern part of the globe the growth process is also affected by 
the time of year. Growth rates are higher during the spring and summer (the lighter 
periods of the year) than during the winter (56). A variety of factors can interfere with 
the rate of growth, including genetic factors, nutrition, general health and/or hormone 
levels. Physical well-being, exercise, sleep and diseases that affect longitudinal growth 
also have impact on the longitudinal growth (7, 25).  
 
Growth hormone and bone 
GH has clear effects on bone physiology and it has been demonstrated that children 
with GHD have decreased bone mineral density (BMD), both by areal and volumetric 
analysis (138). Therapy with GH increases BMD and also markers of bone formation 
such as bone-specific alkaline phosphatase, alkaline phosphatase and osteocalcin (102, 
127). According to the ’the biphasic model‘ of growth (127), GH initially increases 
bone resorption with a concomitant loss of bone. This is followed by a phase of 
increased bone formation (127). After the point when bone formation is stimulated 
more than bone resorption (transition point), bone mass starts to increase. However, a 
net gain of bone mass may take some time (typically 12–18 months in adults receiving 
GH) (127). In children with ISS, BMD is typically decreased relative to controls of the 
same height and bone age. BMD increased significantly following 12 months of GH 
treatment and this was accompanied by increased bone turnover as measured by bone 
formation and resorption markers (102). 
 
 Growth hormone secretion and signalling 
GH is the major hormone of the anterior pituitary and is secreted in a pulsatile 
pattern. The pulsatile pattern arises through the interaction between two peptides 
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secreted from the hypothalamus; somatostatin (SS) which inhibits the secretion of 
GH, and GH-releasing hormone (GHRH) which promotes GH secretion (Figure 3) 
(7, 25). The secretion of GH can vary with for example sleep (7), exercise and 
nutrition (93). The pituitary secretes different isoforms of GH. The major and the 
most potent isoform in serum is the 22 kDa isoform that constitutes approximately 
70% of the GH in blood (17) The 22 kDa isoform is subjected to various post-
translational modifications, including glycosylation, proteolysis and aggregation (106, 
107). This isoform is produced commercially as recombinant biosynthetic human GH 
and is the only isoform given during GH replacement therapy. The other common 
isoforms are the alternative splice product 20 kDa and the proteolytic cleave products, 
5 and 17 kDa, from the 22 kDa isoform (81, 106).  
GHRH SS
IGFBP-3
IGF-I
GH
level
pattern
GH responsiveness receptor
post-receptor
IGF-I
Time
Intracellular signalling
Gene 
transcription
+ -
isoforms
GH secretion
Nutrition
Stress
Physical activity
Sleep
Hormones
GHBP
 
Figure 3. A schematic overview of the GH/IGF-I system. Pituitary secretion of GH is under the control of 
a negative feedback loop (IGF-I, IGFBP-3) caused by the GH-stimulated release of IGF-I. GH release is 
also under the control of GH-releasing hormone (GHRH), and somatostatin (SS).The level and pattern 
of GH secretion over the day is shown in the upper left hand corner of the figure. This illustrates that the 
amount of GH available at any time is variable. In the lower left hand corner of the figure it can be seen 
that GH responsiveness is controlled at different levels, both at the receptor level and post-receptor 
level. 
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Human pituitary GH has two binding sites for the extracellular part of the GH 
receptor (GHR).  
When one GHR molecule binds to site 1 of GH and a second GHR binds to site 2, a 
dimerization of the two GHR molecules occurs. However, today it is known that the 
GHR also exists as a constitutive dimer and is activated by a reorganization of 
receptor subunits as a result of asymmetric placement of two receptor binding sites on 
the hormone monomer (110, 111). GH exerts its effects on the target tissues through 
binding and dimerization of the GHR, and subsequent activation of several 
intracellular signalling pathways (69). The expression of GHR is under the control of 
the GH concentration in the blood and nutritional intake (151). The result is 
activation of a cascade of different intracellular signal pathways leading to the 
stimulation of IGF-I release (25, 128). The process starts by phosphorylation of the 
tyrosine residues in the intracellular domain of the GHR and phosphorylation of 
molecules downstream in the signalling pathway (69). The Janus kinase 2 (JAK2) and 
signal transducers and activators of transcription (STATs) pathway transduce signals 
to the cell nucleus, where activated STAT proteins induce gene expression. The 
JAK2–STAT5 pathway is believed to be the most important pathway for GH-
mediated longitudinal growth. Another important signalling pathway is the MAP 
kinase pathway (69). 
GHBP is present in the blood and is identical to the extracellular part of the GHR. In 
humans, GHBP is believed to be produced by proteolytic cleavage of the extracellular 
domain of the GHR (151). The physiological role of GHBP is unclear. However, in 
vivo it has been shown that GHBP can prolong the half-life of GH and increase the 
effects of GH on bone and growth (16).  
 
Growth hormone treatment  
Although GH has been available for clinical use since the late 1950s (140), it is still not 
known how to treat each individual short child optimally. In the early 1980s, daily GH 
injection was introduced to treat short children and is now the globally accepted 
treatment regimen. In 1986, the GH dose of 33 µg/kg/day was introduced, which is 
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still used today. It was shown that GH-deficient children as a group achieve normal 
height within 3 years after starting treatment (4), although the response to GH 
treatment varied widely within as well as between the different diagnostic groups (for 
example, children with short stature as a result of GHD and those with ISS). Today, it 
is clear that individualized GH treatment results in a much smaller range around the 
target height (94). For the purpose of individualizing treatment, validated multivariate 
regression models estimating GH responsiveness during long-term treatment have 
been developed.  
 
Prediction models 
Many short children will benefit from treatment with GH. The earlier that their short 
stature is detected, the greater the possibility to help them to achieve a normal stature. 
A lot of effort has been put into creating models that accurately predict growth in 
response to GH treatment in order to improve stature in these patients as efficiently 
as possible (3, 8, 41, 44, 101, 141). These evidence-based models for predicting growth 
in response to GH treatment provide an indirect measurement of the individual 
responsiveness to GH (95). The best models available today are able to explain up to 
80% of the variation in growth response to GH, based on auxological data from the 
child and his/her parents(41), compared to 33% using traditional diagnostic criterias 
(97). Highly predictive variables that are used within these models include early 
growth data, the difference between the current height of the child and mid-parental 
height, and maximum spontaneous 24 h GH secretion (3, 8, 41, 44, 101, 141). As 
some parameters such as early growth data and details of parental height may be 
difficult or impossible to obtain, there are advantages to developing models that only 
include parameters that are easily attained at the start of the growth investigation at 
the paediatric unit. To achieve this goal it is necessary to identify novel markers of 
growth response, bone quality and metabolism to ensure optimal treatment for the 
individual child. 
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Individualized treatment 
The idea of individualized treatment of many conditions has received considerable 
attention during the last few years due to potential advantages in terms of drug safety 
and effectiveness. Individualizing treatment will avoid the ‘one size fits all’ concept 
and ensure appropriate treatment for each patient (90). Today, around 10% of the 
patients receiving GH treatment do no benefit from treatment. This is either because 
they are poor responders, non-responders or because the drug is cleared too quickly 
from the circulation. As a result of the use of a standardized dose, this group may also 
be at increased risk of adverse effects (38, 137).  
Complex conditions like cancer, asthma and growth retardation are comprised of 
numerous different subtypes among the affected patients. The different subtypes 
share signs, symptoms and risk factors (68, 120) and it is usually not possible to 
discriminate between them using traditional methods. To establish criteria’s to 
discriminate between the subtypes, large-scale screening techniques like genomics or 
proteomics are most likely required. Besides allowing early detection, these techniques 
can improve the long-term treatment of patients suffering from the disease by 
providing tools for individualizing treatment, monitoring disease progression and 
adjusting the individual doses given depending on disease progression (79, 80). 
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Gene expression studies 
During the last 100 years there have been many techniques used to identify and study 
factors involved in the regulation of longitudinal growth.  
This section focus on the development of the techniques that paved the way for 
modern high-throughput techniques that made it possible to study the expression of 
multiple genes at the same time. 
Traditionally, one studied the expression of mRNA from known candidate genes 
using somewhat labour-intensive, low-throughput techniques, like Northern blot and 
RNase protection assays. The discovery of the polymerase chain reaction (PCR), over 
20 years ago, was a milestone in the study of gene expression (105). After this 
discovery, newer and more powerful technologies such as quantitative reverse 
transcription PCR (QRT-PCR) and DNA chips or microarrays were developed (105). 
Since 1995, when microarray methods were first used (150), this technology has been 
applied to a variety of different research fields and numerous statistical tools have 
been developed for evaluating the vast amount of data that are generated. The 
microarray technique has enabled the rapid and simultaneous comparison of the 
mRNA levels of thousands of genes in a wide range of biological samples using very 
low quantities of starting material. This process is generally referred to as genomics or 
transcriptomics. This has made microarray technology a suitable tool with which to 
explore the complex gene response patterns and regulatory pathways involved in 
human diseases (116).  
There are many different microarray technologies but they all share the same basic 
principles. Unknown mRNA from the sample to be analysed is hybridized to an 
ordered array of DNA sequences corresponding to known genes or expressed 
sequence tags. A DNA microarray chip may contain DNA sequences corresponding 
to more than 30 000 human genes, ordered on a miniature glass slide (116). Every 
mRNA, or transcript, is labelled with a marker, for example, a fluorescent dye. After 
the processing of the chip they are placed in a reader where the location and intensity 
of the resulting signals give an estimate of the quantity of each transcript in the 
sample. It is thus possible to measure all transcripts in the sample (i.e. the 
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transcriptome) (116). Microarrays can also be used to search for DNA polymorphisms 
(single nucleotide polymorphisms, or SNPs) or to study protein interactions.  
However, the mRNA levels measured do not always reflect the corresponding protein 
levels due to mRNA breakdown and the specific post-transcriptional modifications of 
the proteins (19, 67). In yeast it has been shown that the correlation between the 
expression levels of mRNAs and proteins are no higher than 0.54 (57, 61). Poor 
correlations between mRNA and protein abundance have also been found in the 
human liver (correlation coefficient, 0.48) (11). 
 
Proteomics and protein regulation 
The term proteome refers to the total set of proteins expressed by a cell, tissue or 
organism at a given time point (46). Proteomics is defined as the analysis of the entire 
protein complement expressed by a genome (46), and can be used to study the 
proteins expressed by the genes which are responsible for the biochemical processes 
taking place within the cell. This provides an advantage over studying the genome 
which does not reflect the dynamics that occur due to the different conditions that 
cells are exposed to. The proteome is highly dynamic and the same protein is 
expressed in different forms that cannot be predicted from mRNA analysis (12). 
 
The development of new techniques has been a prerequisite for proteomics and has 
made it possible to shift focus from the time consuming study of single candidate 
proteins to the study of multiple proteins at the same time. It has also made it possible 
to move towards a better understanding of gene function.  
 
Regulation of the proteome is highly complex and it can be modified at any of the 
many stages involved in the translation of genes into proteins (Figure 4). 
Modifications include alternative mRNA splicing, mRNA degradation, post-
translational modifications at the protein level and associations with other proteins. 
All together this gives rise to numerous distinct proteins.  
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Figure 4: A schematic illustration of, ’the central dogma of molecular biology‘, the process from DNA to 
functional protein. Each step that can affect the protein end-product produced from the original gene is 
shown. The figure is used with permission from Graves et al. (60).  
 
Biomarker discovery 
The common goal of most proteomic studies has been to identify biomarkers which 
are related to a certain disease mechanism and can be used for screening (early 
detection), prognosis, monitoring of drug response or to assess disease 
progression/predisposition. Proteomics can also be used at an early stage in clinical 
studies of new drugs to examine clinical effects and toxicological responses (134). 
Proteomic technologies have successfully been used to identify novel biomarkers in a 
wide range of diseases (45, 62, 133). 
 
Each cell type has a specific set of proteins at a specific time and condition. The set of 
proteins will change when the conditions change (e.g. in response to disease), making 
proteins promising targets in biomarker discovery. By using proteomics it is possible 
to study changes in protein expression patterns associated with a certain disease or in 
response to a certain drug. Typically, the changes observed involve either up or down 
regulation of one or more expressed proteins; however, sometimes a protein is no 
longer present or its pattern of post-translational modifications is altered (62, 133). 
There may also be expression of a previously non-transcribed protein. 
 
Much of the focus in detecting clinically important biomarkers has centred on the use 
of readily available samples, such as serum, urine, amniotic fluid and cerebrospinal 
fluid. These fluids are like ’fingerprints‘, showing the status of the body at a given 
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time, and can be collected in sufficient quantities to allow protein profiling. Being easy 
to obtain they are suitable as samples for use in the early detection of lethal diseases 
like cancer.  
 
The human plasma proteome  
The plasma proteome is the largest and the most complex of the human proteomes 
(12). Serum samples, which are composed of plasma without fibrinogen or the other 
clotting factors, are used in many proteomic studies. Plasma and serum are often the 
first-choice samples when screening for biomarkers, because they are accessible and 
contain large amounts of protein (12). The blood has been estimated to contain over 
10 000 of the proteins present in the human body (2, 13).  
 
Plasma that circulates in the human body contains a myriad of proteins from different 
origins. However, only a small number of the proteins present in plasma are true 
plasma proteins that actually have functions in the circulation. Apart from the true 
plasma proteins, plasma contains proteins leaked by tissues, hormones, proteins 
fragments, etc. (Table 2).  
 
The plasma proteins have a dynamic range higher than 10 orders of magnitude (9, 12), 
ranging from the most abundant protein, albumin, that constitute over half of the 
plasma proteome and is typically found in concentrations between 35 and 50 g/L, 
down to cytokines, with concentrations of just a few ng/L (Figure 5).  
 
It has been calculated that ’true‘ plasma proteins (i.e. proteins that carry out their 
function in the plasma) probably would yield around 50 000 forms, but by the 
addition of all proteins contributing to the plasma proteome by tissue leakage, one will 
end up with a theoretical maximum number of around 500 000 protein forms in 
plasma, including essentially the entire human proteome (12). 
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Most of the instruments used today for proteomic analyses have limitations regarding 
the 10–12 orders of magnitude of the plasma proteome (9, 12). Mass spectrometry 
which is the most sensitive of the high-throughput techniques has the limitation of a 
dynamic range of three magnitudes. If used in combination with an HPLC system, the 
dynamic range can be increased to 104–106 (9, 12). Therefore, depletion and 
fractionation strategies are often used to decrease the diversity and complexity of the 
samples. Depletion of proteins in serum is usually performed using antibodies or 
beads designed against certain proteins. Fractionation is usually performed using 
different types of columns or beads with certain biochemical properties to which 
proteins bind and are subsequently eluted using individual buffers with different 
eluting properties (typically pH). Depletion and fractionation strategies are also used 
because the high dynamic range of plasma proteins tends to mask the presence of 
proteins or peptides with low abundance (9, 12). Most of the potential biomarkers are 
secreted into the bloodstream in low concentrations (9, 12). The most well-known 
biomarker for prostate cancer, prostate-specific antigen (PSA), is present in the low 
pg/mL concentrations (9, 12). 
Dynamic range of the blood proteome
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Figure 5: This figure demonstrates the high dynamic range of proteins present in a plasma sample. The 
figure was kindly provided by Bio-Rad. 
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Table 2. Putnam’s classification of plasma proteins divided into functional groups, 
elaborated and described from a functional viewpoint by Anderson et al. (12).  
 
Group Description  
Proteins secreted by tissues 
acting in plasma  
Classical plasma proteins that are mostly secreted by the 
liver and intestines. 
Immunoglobulins Antibodies that circulate the blood stream.  
Long distance receptor 
ligands  
Peptide and protein hormones present in a range of sizes, 
for example insulin.  
Local receptor ligands  Cytokines and other short mediators of cell responses that 
mediate local interactions 
between cells followed by dilution into plasma in low 
ineffective levels.  
Temporary passengers  Non-hormone proteins that traverse plasma on their way to 
their primary site of function. 
Tissue leakage products  Proteins that normally function inside cells but are released 
into plasma as a result of cell death or damage, e.g. 
lysosomal proteins 
Aberrant secretions  Released from tumours or diseased tissue, presumably not 
as a result of a functional requirement. 
Foreign proteins  Proteins from infectious organisms or parasites that are 
exposed to or released into the bloodstream. 
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Proteins and genes identified and studied in Papers I–V 
Adiponectin  
Besides being the major regulator of longitudinal growth, GH exerts direct effects on 
body composition through anabolic and lipolytic actions (82, 160). The function of 
adipose tissue was formerly considered to be mainly fat storage. Today, it is well 
established that adipose tissue produces and secretes a large number of growth factors 
and hormones called adipokines (20, 166). Many adipokines have profound effects on 
other tissues in the body (20), including bone (47, 131). Furthermore, it has been 
observed that many obese children have a normal longitudinal growth rate in spite of 
having very low circulating GH levels (135). This may suggest that adipose tissue-
derived factors could affect GH responsiveness, or that adipokines may have direct 
effects on longitudinal growth. 
The circulating levels of most adipokines, including leptin, are increased in obese 
subjects (65). However, the adipokine, adiponectin, that is studied in Paper I, is an 
exception to this rule. Levels of adiponectin, which is predominately expressed by the 
adipocytes in both subcutaneous and visceral fat (1), decrease as the amount of 
adipose tissue increases (65). Adiponectin influences glucose and lipid metabolism and 
is decreased in obese individuals and patients with type 2 diabetes (168, 176). In 
addition, adiponectin seems to play a role in cell adhesion and participates in the 
regulation of cell proliferation and growth, and tissue remodelling (132, 173, 177). It 
has also been shown that short children born small for gestational age (SGA) who 
show catch-up growth have significantly lower adiponectin levels than those who do 
not show catch-up growth (36). Furthermore, GH treatment in children with SGA 
leads to lower adiponectin levels (36, 72, 130). Adiponectin has also been shown to 
directly regulate GH secretion in vitro in pituitary cells by binding to the adiponectin 
receptor (144, 159). In turn, GH can induce adiponectin receptor 2 expression (53), 
whereas adiponectin decreases the expression of this receptor (31). These findings 
suggest the presence of a negative feedback loop between adiponectin and GH.  
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Cartilage oligomeric matrix protein 
COMP is a secreted 550 kDa protein that is predominantly synthesized by 
chondrocytes and is found primarily in the extracellular matrix of cartilage, ligaments, 
and tendons (27, 29).  
COMP is known to interact with collagen types I, II, and IX in a divalent cation-
dependent manner. COMP and its proteolytic fragments are released into synovial 
fluid and serum on joint degradation, suggesting a possible role of COMP in the 
assembly and maintenance of the extracellular matrix (149). Mutations in the COMP 
gene are associated with pseudoachondroplasia and multiple epiphyseal dysplasia, 
conditions that are both characterized by short stature (27, 29).  
 
High-density-lipoprotein-related markers  
Apolipoprotein (Apo) A-I, A-II, C-I, and C-III, and serum amyloid A4 (SAA 4) and 
transthyretin (TTR), which are all markers of GH response in this study, are part of 
the high-density lipoprotein (HDL) (153, 157, 178). However, Apo A-II, Apo C-I, 
Apo C-III and SAA 4 have also been found in very-low-density lipoproteins (VLDL) 
and low-density lipoproteins (LDLs) (10, 178). 
HDL is known as the ‘good’ cholesterol because of its role binding unhealthy 
cholesterol from the blood and transporting it to the liver where the cholesterol is 
excreted or re-utilized (54).  
Today, not much is known about the effects of GH on either the apolipoproteins, 
TTR or SAA 4.  
There are contradictory results regarding the effects of GH treatment given as daily 
subcutaneous injections on the HDL which carries these proteins (71, 100, 104). This 
is discussed in more detail in the discussion section in Paper V. It was also seen that 
HDL decreased after a single large GH dose which created a GH plasma profile with 
a high peak after the injection (142, 143).  
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A short summary of the known functions of the HDL-related biomarkers identified: 
Apolipoprotein A-I: The most common protein of the HDL molecule, Apo A-I 
promotes cholesterol efflux from tissues to the liver for excretion and may confer an 
important protective action against the accumulation of platelet thrombi at sites of 
vascular damage. (180). 
 
Apolipoprotein A-II: Apo A-II is the second most common protein of the HDL 
molecule. Apo A-II-deficient mice showed improved insulin sensitivity, whereas 
transgenic mice over-expressing murine Apo A-II showed insulin resistance and 
obesity (32). Apo A-II has also been suggested as a candidate gene in type 2 diabetes 
(49, 63, 170). 
 
Apolipoprotein C-I: Apo C-I is a major plasma inhibitor of cholesteryl ester transfer 
protein and appears to interfere directly with free fatty acid uptake (153). 
Hypertriglyceridaemia and increased atherosclerosis have been shown to be a direct 
consequence of over expression of Apo C-I (39). In obese mice, over expression of 
Apo C-I leads to insulin resistance (123). Furthermore, Apo C-I has been reported to 
increase HDL levels in blood (43). 
 
Apolipoprotein C-III: Apo C-III is primarily expressed as a VLDL. Apo C-III is an 
inhibitor of lipolysis and its expression may contribute to the hypertriglyceridaemia 
and atherogenic lipoprotein profile observed after retinoid therapy (153, 171). High 
Apo C-III concentrations increase the risk of coronary heart disease associated with 
high triglyceride levels (73). 
 
Serum amyloid A4: The function of SAA 4 is largely unknown. SAA 4 is a minor acute-
phase reactant in humans (i.e. it does not change as much as other SAAs in response 
to inflammation). Furthermore, SAA 4 may be an indicator of nutritional state (179).  
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Transthyretin: Transthyretin is well known as a marker of nutrition (165). In addition to 
its functions as a carrier of serum thyroxine and triiodothyronine and a transporter of 
retinol (vitamin A) (52)  
 
Haemoglobin beta 
Haemoglobin is present in the red blood cells and is an iron-containing oxygen-
transport metalloprotein. Haemoglobin transports oxygen from the lungs to the rest 
of the body where it releases the oxygen. In patients with thalassemia who have 
impaired haemoglobin beta function, BMD is decreased (48, 148). Furthermore, 
growth retardation and GH/IGF-I/IGFBP-3 hormone axis dysfunction, have been 
reported in patients with thalassemia major (over production of defective 
haemoglobin beta) (86). It has also been shown that haemoglobin beta is upregulated 
during GH-releasing hormone analogue treatment (147). Although the molecular 
mechanisms linking the proteins identified to the biological activity of GH and IGF-I 
remain to be clarified, the results suggest that they represent potential biomarkers of 
GH and/or IGF-I action. 
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AIM OF THE STUDY 
The overall aim of the studies included in this thesis was to identify novel genes and 
proteins that could be used as markers for GH treatment response and that are of 
possible importance for both GH-mediated regulation of longitudinal growth in 
children and GH treatment response with respect to longitudinal growth and bone 
mineralization. 
 
Specific aims  
I.  To investigate the relationship between growth response to GH treatment and 
adiponectin in short prepubertal children. 
 
II.  To use genomics to identify novel GH- and IGF-I-induced genes in a GH target 
tissue. 
 
III–V. To elucidate if a pharmacy-proteomic approach can be used to identify novel 
serum markers of the growth response to GH treatment and changes in bone 
mineralization during GH treatment. 
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PATIENTS AND METHODS 
The patients and methods used in this thesis are described in detail in the materials 
and methods sections of each individual paper. A shorter, more general, overview of 
the methods is presented below. 
 
Ethical approvals 
All studies were approved by the ethical boards of the University of Gothenburg (for 
patients from Gothenburg and Halmstad) and in Papers IV–V from the ethical boards 
in Umeå, Uppsala and Malmö, as well as the Medical Product Agency of Sweden. 
Written informed consent was obtained from all parents and from children if old 
enough. All trials included were performed in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines.  
 
Patients 
This thesis includes patients from the Swedish National Registry for GH treatment 
and/or clinical trials. In Paper I 82 out of the 94 patients, and in Papers II and III all 
patients were included in the Swedish National Registry and the Swedish GH trials 
(14). There was an overlap between the study groups in Papers I–III; 25 patients are 
present in both Papers I and II, 20 patients are present in both Papers I and III, 27 
patients are present in Papers II and III, and 8 patients are present in all three studies 
(illustrated in Figures 6 and 7). In Papers IV and V all 128 patients were included in 
the GH dose clinical trial (TRN 98-0198-003). 
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546 GH-treated short children 
from Swedish National GH 
Registry and clinical trials 
32 children with ISS Paper III (GH respons) 
82 GH-treated short 
children Paper II (COMP) 
94 GH-treated short children 
Paper I (Adiponectin) 
 
Figure 6: The procedure for study group selection in Papers I–III. 
 
Figure 7: The number of children included in Papers I–III, sorted by GHmax24 h from lowest (left) to 
highest. Each vertical bar represents one child. 25 patients are present in both Papers I and II, 20 
patients are present in both Papers I and III, 27 patients are present in Papers II and III, and 8 patients 
are present in all three studies. 
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Adiponectin study (Paper I) 
To study the relationship between GH and adiponectin, 94 short prepubertal Swedish 
children (19 girls, 75 boys) were treated with daily injections of GH (dose range, 26–
69 µg/kg/day) and followed for at least 1 year. The clinical characteristics of the 
patients are given in Table 1 of Paper I. Of the 94 children, 56 were diagnosed as 
having isolated GHD and 38 were short but did not have GHD. The children were 
well nourished, free from chronic disease and had no dysmorphic features.  
 
Cartilage oligomeric matrix protein study (Paper II) 
To verify the microarray analyses that COMP was regulated by GH, 113 short 
prepubertal Swedish children (14 girls, 99 boys) with a broad range of peak GH 
response (GHmax) during an AITT were treated with daily injections of GH (33 
µg/kg/day) and followed for at least 1 year. The clinical characteristics of the patients 
are given in Table 2 of Paper II. Of the 113 children, 82 were diagnosed as having 
isolated idiopathic GHD and 31 were short but did not have GHD. The children were 
well nourished, free from chronic disease and had no dysmorphic features.  
 
Growth hormone responder study (Paper III)  
To identify serum biomarkers that could be used to discriminate between a good or 
poor growth response to GH treatment in short prepubertal children receiving GH 
treatment, the 40 children with the highest and the 40 children with the lowest first 
year growth response from within the cohort were selected. From this group of 80 
children, 51 children with ISS and a maximum peak of GH secretion (GHmax) on the 
AITT > 5 µg/L were identified. 
 
Growth hormone response and bone study (Papers IV–V) 
To identify serum biomarkers that correlated with changes in growth, bone 
mineralization and bone volume in response to GH treatment in short prepubertal 
children, the per-protocol population from the GH dose clinical trial (TRN 98-0198-
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003) which consisted of 128 short prepubertal children (94) was used. Study patients 
were randomized either to a group receiving an individualized (two-thirds of patients) 
or a standard GH dose (one-third of patients). The standard GH dose was 43 
µg/kg/day. The individualized GH dose comprised one of six different doses (mean, 
49 µg/kg/day; range, 17–100 µg/kg/day). The GHmax ≥ 32 U/L (old 10 µg/L) on an 
AITT or of the spontaneous GH secretion over a 24 h period was used to classify the 
patients as having either ISS (n=89) or short stature due to GHD (n=39). Clinical data 
for the patient groups are presented in Table 1, Paper IV and V. 
 
Study design 
Pre-treatment investigations: Endocrine investigations were performed during the pre-
treatment year. The children underwent both an AITT and a 24 h secretion profile (5, 
26, 96). Blood samples were obtained for determination of hormone and protein 
concentrations. 
Blood samples were taken at the start of the study, and 1 week, 1 month, 3 months and 1 
year after the start of GH treatment. The samples were taken at health care units in 
Sweden approximately 24 h after the last GH injection. The samples were stored at  
–70 °C and were not thawed until the time of analysis.  
Dual-energy X-ray absorptiometry (DXA) measurements and growth evaluations were 
performed at the paediatric units in the GH dose clinical trial (Papers IV and V) at the 
start of the study, and after 1 and 2 year of GH treatment. 
 
Growth evaluation 
The childhood component (87) of the Swedish population-based growth reference 
values (6) was used for the height-related inclusion criteria and to express the 
prepubertal height for weight (6) and body mass index (89) of the patients. Reference 
standards of newborns were used for standard deviation score (SDS) at birth (126).  
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Hormone and protein measurements 
Adiponectin (Paper I): Concentrations of serum adiponectin were measured in 
duplicate by an ELISA (R&D Systems Inc., Minneapolis, MN). The assay has a 
detection limit of 1 ng/mL. All samples were analysed using the same assay batch, and 
samples from each patient were run in the same assay. In our laboratory, the assay had 
an interassay CV of 6.9% at 8.8 µg/mL and an intraassay CV of 3.6% at 14.5 µg/mL. 
 
COMP (Paper II): Concentrations of serum COMP were measured in duplicate by 
an ELISA (Kamiya Biomedical Comp, Seattle, WA). The assay has a detection range 
of 10–80 ng/mL. All samples were analysed using the same assay batch, and samples 
from each patient were run in the same assay. Only COMP values with an intraassay 
CV below 15% were included. In our laboratory, the assay had an interassay CV of 
10.0% at 1.0 µg/mL and 8.7% at 1.3 µg/mL.  
 
GH: GH measurements were performed at the GP-GRC laboratory (SWEDAC 
accredited no 1899) at the University of Gothenburg using monoclonal (Wallac, 
Turkku, Finland),or polyclonal antibody-based immunoradiometric assay (Pharmacia 
Diagnostics, Uppsala, Sweden)  (81).  
 
IGF-I: Concentrations of serum IGF-I were measured by an IGFBP-blocked 
radioimmunoassay (RIA) without extraction and in the presence of an approximately 
250-fold excess of IGF-II (Mediagnost GmbH, Tubingen, Germany) Published 
reference values were used to assess the results of analyses of IGF-I (117). 
 
IGFBP-3: Serum IGFBP-3 concentrations were measured by a polyclonal antibody-
based RIA (Mediagnost GmbH, Tubingen, Germany). Published reference values 
were used to assess the results of analyses of IGFBP-3 (118).  
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Dual-energy X-ray absorptiometry (Paper V) 
To asses bone mineral content (BMC), bone area (BA) and BMD, whole body DXA 
scans were obtained using either a Lunar DPX-L scanner (GE Medical, Madison, WI) 
or a Lunar Prodigy (GE Medical). The results were comparable across DXA systems, 
and only small differences were detected between Lunar’s Prodigy and DPX systems 
(74).  
DXA scan reproducibility (CV) for the Lunar Prodigy system has been reported to be 
0.18 to 1.97% for total body bone measures, and 0.96 to 6.91% for regional bone 
measures (121). 
 
Cell culture (Paper II) 
Cultured human primary chondrocytes were established from a surgically removed 
extra thumb from a 1-year-old boy. Cells were cultured in Dulbecco’s modified 
Eagle’s medium DMEM/F12 (1:1, v/v) (Gibco BRL, Paisly, UK) containing 10% 
(v/v) fetal calf serum (FCS; Bio Whittaker, Verviers, Belgium), Fungizone (500 µg/L; 
Gibco), gentamicin sulphate (50 mg/L; Biochrom KG, Berlin, Germany), L-glutamine 
(2 mmol/L; Gibco) and L-ascorbic acid (100 mg/L; Merck, Darmstadt, Germany) in a 
humidified 5% CO2 atmosphere at 37 °C. Cells were routinely tested and found to be 
negative for mycoplasma infections. Cells in passage 3 were used for the experiment. 
Cells were grown to confluence and then rinsed twice with DMEM without phenol 
red (Gibco) before they were starved for 27 h in DMEM without phenol red and 
without serum. They were then stimulated with GH (50 ng/mL Genotropin, batch 
28157B51; 36IE/KY (12 mg), supplied by Pharmacia) or IGF-I (50 ng/mL, IGF-I; lot 
99H0295, Sigma, St. Louis MO) for 12 h before being harvested for RNA 
preparation. 
 
Analysis of microarray data (Paper II) 
Preparation of cRNA and microarray hybridization was according to standard 
protocols. After visual inspection for hybridization artefacts of the scanned output 
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files, Affymetrix software Microarray Suite 5.0 was used to analyse differences in gene 
expression between GH- or IGF-I-stimulated chondrocytes compared with controls. 
Samples from each treatment group and the control group were run in duplicate. The 
two GH and two IGF-I microarrays were compared separately with the two control 
microarrays, creating four comparison files for GH versus controls and four 
comparison files for IGF-I versus controls. Genes with different expression levels in 
chondrocytes cultured with GH or IGF-I versus controls were identified. A fold 
change of 1.5 was considered significant. 
 
Serum denaturation and fractionation (Papers III–V) 
Frozen serum samples were thawed on ice and spun at 10 000 rpm for 10 min at 4 °C. 
Each serum sample (10 µL) was denatured by the addition of 20 µL of U9 buffer (9 M 
urea, 2% CHAPS, 50 mM Tris-HCl, 1% DTT, pH 9.0) and vortexed at 4 °C for 30 
min.  
 
Sample fractionation was performed on a Q HyperD F resin plate (180 µl resin) 
(Ciphergen, Fremont, CA). The plate was prewashed and equilibrated with U1 
solution (1 M urea, 0.2% CHAPS, 50 mM Tris-HCL, pH 9) prior to the addition of 
samples to the 96-well fractionation plate. The anion exchange fractionation included 
the following elution steps: (1) 50 µM Tris-HCL, 0.1% OGP (a nonionic detergent, b-
D-glucopyranoside), pH 9; (2) 50 µM HEPES, 0.1% OGP, pH 7; (3) 100 µM Na 
Acetate, 0.1% OGP, pH 5; (4) 100 mM Na Acetate, 0.1% OGP, pH 4; (5) 50 µM Na 
Citrate, 0.1% OGP, pH 3; and (6) 33.3% isopropanol, 16.7% acetonitrile, 0.1% TFA 
(trifluoroacetic acid).  
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SELDI-TOF MS (Paper III-V) 
To identify protein biomarkers of interest, the surface-enhanced laser 
desorption/ionization time-of-flight (SELDI-TOF) technique was used (Figure 8). 
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Figure 8: Schematic illustration of the SELDI-TOF technique. Samples are applied on the spots of the 
protein arrays. Thereafter, the arrays are loaded into the machine and laser is fired upon the spots. The 
proteins are eluted and travel towards the detector and mass over charge spectra (m/z) are created. 
 
SELDI-TOF is an array-based high-throughput mass spectrometry-based technique, 
that has been successfully used to identify biomarkers/proteins in many different 
sample types and for many diseases (68, 84). SELDI-TOF technology is based on 
mass spectrometry, where retentate chromatography is performed on ProteinChip 
Arrays with varying chromatographic properties (Figure 9). Each array contains a 
chemically pre-activated surface (anion exchange, cation exchange, metal affinity and 
reverse phase) (Figure 9). The chemical surfaces are used to capture subsets of 
proteins for protein profiling analysis. Samples are applied on arrays which are loaded 
into the SELDI-TOF instrument. Proteins are eluted by laser desorption/ionization. 
Ionized proteins are detected and the mass is determined by TOF mass spectrometry, 
resulting in mass spectra reflecting the protein expression (Figure 8), where the peak 
intensities are proportional to the amount of the specific protein.  
 
In the TOF analyser the ions are accelerated by an electric field prior to entering the 
field-free flight tube. The time to reach the detector is a function of their mass and 
charge (m/z). The lighter ions will reach the detector first because of their higher 
velocity.  
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Figure 9: Various ProteinChip array surfaces. Chromatographic surfaces are composed of reversed-
phase (H50), ion exchange (CM10 and Q10), immobilized metal-affinity capture (IMAC30) or normal-
phase (NP20) chemistries. The figure was provided by Bio-Rad. 
Serum samples were thawed, denatured and fractionated using anion-exchange beads 
in a serum fractionation kit (Bio-Rad Laboratories, Hercules, CA) according to 
protocols provided by Bio-Rad Laboratories. The fractionated serum samples were 
analysed on weak anion-exchange (CM10), immobilized metal-affinity capture 
(IMAC30) and reversed-phase (H50) arrays according to the protocols described in 
Papers III–V.  
In brief, the samples were bound to the arrays and SPA matrix was added. The arrays 
were analysed using the SELDI-TOF instrument generating TOF. To minimize 
experimental variation, all samples were randomized and analysed concurrently within 
1 week by the same operator. In addition, one reference serum sample was randomly 
applied on each array and evaluated. The mass accuracy was calibrated in the 
molecular range of 5–18 kDa using external calibrators from Bio-Rad Laboratories.  
 
Data pre-processing 
Data handling was performed using ProteinChip Data Manager (Bio-Rad 
Laboratories). All spectra were baseline-subtracted and normalized according to total 
ion current. Settings for peak identification and clustering of peaks across multiple 
spectra were first pass signal-to-noise ratio (S/N) > 5 in 15% of all spectra and second 
pass S/N > 3 in Paper III and (S/N) > 3 in 15% of all spectra and second pass S/N 
> 2 in Papers IV–V, with a cluster mass window of 0.3% of the mass.  
Spectra were visually inspected and patients were excluded from further data analysis 
if profiles clearly differed between the duplicate samples or if the overall quality was 
low in one or both of the spectra (i.e. high noise, overall low peak intensity or an 
abnormal normalization factor in combination with visually deviating spectra).  
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Only patients for whom there were two high-quality mass spectra for the relevant 
array and time point were included in further statistical analyses.  
 
Protein quantification (Papers III–IV)  
To use the Microcon filtration cut-off membranes (YM30, Millipore, USA) and to 
perform the ACN precipitation in preparation of the 1D SDS-PAGE analysis it is of 
importance to know how much protein was loaded. 
 The protein concentration of a 1 µL sample was determined using the NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, USA) according 
to manufacturer’s instructions. The protein concentrations were measured at 280 nm.  
 
In some cases the protein concentration was measured using the DC Protein Assay 
(Bio-Rad, Munich, Germany) in a microplate assay mode. The standard curve was 
made up of four concentrations of bovine serum albumin (Bio-Rad), ranging from 0.1 
to 1.5 mg/mL. The assay was performed according to manufacturer’s instructions and 
the UV-absorbance was measured at 750 nm. 
 
Protein purification strategy (Papers III–IV)  
To prepare the fractionated serum for 1D SDS-PAGE analysis and to get as good a 
resolution as possible in the low mass region, the following two strategies were used:  
 
1. Microcon filtration cut-off membranes (YM30, Millipore, USA) with a cut-off of 30 
kDa were used according to manufactures instructions to concentrate the fractionated 
serum approximately 100 times. 
The filtrate obtained was analysed on NP20 (hydrophilic normal phase) arrays in the 
SELDI-TOF machine to test if the filtration had been successful.  
 
2. ACN precipitation of major serum protein components. Human serum (20mL) was 
transferred to a LoBind micro-centrifuge tube (Eppendorf, Cambridge, UK), diluted 
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with 40 mL of 18.2MV water and vortexed to mix. ACN (90mL) was added and the 
sample sonicated for 10 min in a U300 ultrasonic water bath (Ultrawave Ltd., Cardiff, 
UK). The sample was vortexed briefly then sonicated for a further 10 min. The 
protein precipitate was pelleted by centrifugation at 12 000 g for 10 min at room 
temperature in a fixed rotor EBA 12-R centrifuge (Hettich, Tuttlingen, Germany). 
The supernatant was transferred to a clean LoBind tube and evaporated to dryness in 
an HT-4 centrifugal evaporator (Genevac, Ipswich, UK) with no heating (91).  
 
1D SDS-PAGE analysis (Papers III–V) 
Fractionated and purified serum was loaded onto the gel to separate the proteins. The 
1D SDS-PAGE was run under denaturing conditions using NuPAGE® Bis-Tris gels 
4–12% and NuPAGE® MES (3-N-morpholino ethane sulfonic acid) SDS Running 
Buffer, both from Novex (San Diego, CA, USA). 1x NuPAGE® MES Sample Buffer, 
0.05M DTT and proteins samples were mixed and denatured for 3 min at 95 ˚C prior 
to loading. NuPAGE® Antioxidant was added to the running buffer in the upper 
buffer chamber of the Xcell SureLock™ Mini-Cell (Novex, San Diego, CA, USA) to 
keep the proteins in a reduced state. Gels were run at 200 V for 35 min using a 
POWER PAC 1000 (Bio-Rad, Hercules, CA, USA) power supply. Staining was 
performed using Colloidal Blue Staining Kit (Novex, San Diego, CA, USA). Precision 
Plus Protein Unstained Standards were used as the molecular weight standard and the 
gels were scanned using a Fluor-S MultiImager and Quantity One Software, all 
purchased from Bio-Rad (Hercules, CA, USA). 
 
Passive elution (Papers III–V) 
To be able to use mass spectrometry analyses for protein identification, the proteins in 
the low molecular weight range were passively eluted from the 1D SDS-PAGE gel by 
excising the band after Coomassie staining. The excised band were washed with 50% 
acetonitrile (ACN)/50 mM Ambic (3 x 15 min or until gel slice was destained). The 
gel pieces were dehydrated in 100% ACN, heated to 50 °C for 5 min and placed in a 
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Speed vac until completely drained. Thereafter, 45% formic acid, 30% ACN and 10% 
isopropanol were added to the cover bands and the samples were sonicated for 30 
min in a water bath at room temperature and left at room temperature for 3–4 hours 
before subsequent analysis. 
A small amount of the passively eluted proteins was analysed on a NP20 array to 
confirm that the same m/z identity and peak pattern could be seen as in the original 
SELDI-TOF spectra profile.  
 
Protein identification  
Immunodepletion (Papers III–V) 
To confirm the identity of the biomarkers of interest, immunodepletion was 
performed using antibodies and dynabeads (Invitrogen, Carlbad, CA) coated with anti-
rabbit immunoglobulin G (IgG). Dynabeads were washed twice in 1 mL PBS (PAA 
Laboratories GmbH, Pasching, Austria) and resolved in 0.5 mL PBS. Four µg of 
antibody was added per 50 µL dynabeads and incubated over night at 4 °C on a 
rotation mixer (REAX 2, Heidolph, Schwabach, Germany). Unbound antibodies were 
removed by washing twice in 1 mL PBS. The beads were resolved in 50 µL PBS. 
Twenty µL of fractionated serum were then added followed by incubation for 1 h at 4 
°C on a rotation mixer and two washes in 1 mL PBS. The depleted serum was 
analysed on the same arrays as the biomarkers were found on.  
 
Destaining of proteins and in-gel protein digestion (Paper III) 
To prepare the gel pieces corresponding to the protein biomarkers of interest for 
protein identification, destaining of the Coomassie-stained gel pieces was necessary. 
Destaining of the excised gel pieces was performed by adding 100 µL of 100 mM 
ammonium bicarbonate/acetonitrile (1:1, vol/vol) and the samples were incubated for 
30 min on a shaker. Thereafter, the samples were dehydrated by adding 500 µL of 
acetonitrile. The samples were incubated at room temperature on a shaker until the gel 
pieces had shrunk and became white. Finally, the acetonitrile was removed (154).  
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Trypsin digestion was done by adding trypsin buffer to cover the dry gel pieces 
(typically, 50 µL or more, depending on the volume of the gel matrix) and the sample 
was put in a fridge for 120 min. Approximately 10–20 µL of ammonium bicarbonate 
buffer was added to cover the gel pieces and keep them wet during enzymatic 
cleavage. The tubes containing the gel pieces were placed into an air circulation 
thermostat and incubated for 30 min at 55 °C (154). Finally, 100 µL of extraction 
buffer (1:2 (vol/vol) 5% formic acid/acetonitrile) was added to each tube and the 
samples were incubated for 15 min at 37 °C on a shaker (154). 
 
Nanoflow liquid chromatography/tandem MS (LC -MS/MS) 
Fourier transform ion cyclotron MS (FT/ICR MS) (Papers III–IV) 
Two-microliter sample injections were made with an HTC-PAL autosampler (CTC 
Analytics AG, Zwingen, Switzerland) connected to an Agilent 1100 binary pump 
(Agilent Technologies, Palo Alto, CA, USA). The peptides were trapped on a 
precolumn (45 × 0.075 mm i.d.) packed with 3 µm C18-bonded particles and 
separated on a reversed phase column, 200 × 0.050 mm. Both columns are packed in-
house with 3 µm Reprosil-Pur C18-AQ particles. A 40 min gradient 10–50% CH3CN 
in 0.2% COOH was used for separation of the peptides. 
Nanoflow LC-MS/MS was performed on a hybrid linear ion trap-FTICR mass 
spectrometer (LTQ-FT, Thermo Electron, Bremen, Germany). The spectrometer was 
operated in data-dependent mode, automatically switching to MS/MS mode. MS-
spectra were acquired in the FTICR, while MS/MS-spectra were acquired in the LTQ-
trap. All the tandem mass spectra were searched by MASCOT (Matrix Science, 
London, UK) against the SwissProt 5.16 database. The search parameters were set to: 
MS accuracy 5 ppm, MS/MS accuracy 0.5 Da, one missed cleavage by trypsin allowed, 
fixed propionamide modification of cysteine and variable modification of oxidized 
methionine. 
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Statistical methods 
Statistical analyses were performed using SPSS (version 11.5 and 12.0.1, SPSS, Inc., 
Chicago, IL), Origin™ (version 5.0, Microcal™ Software, Inc., Northampton, MA) 
and Matlab software (version 7.7.0 R2008b, The Mathworks). Data are presented as 
means ± SD. The Pearson product-moment correlation coefficient was used to 
calculate correlations at the individual level when the data were normal distributed, 
otherwise a Mann–Whitney–Wilcoxon non-parametric test was used. Independent t-
tests were used to test significance at the group level and one way analysis of variance 
(ANOVA) was used to study changes within the groups between different time 
points. 
 
To identify potential biomarkers of interest, serum proteomic profiles were compared 
before and after 1 year of treatment. In addition, changes in profiles over 1 year of 
treatment were analysed. Proteomic data from the different array surfaces were 
analysed individually as well as merged and analysed together. The peak intensity data 
were analysed either directly after pre-processing or log transformed. The peak data 
were thereafter analysed with multidimensional scaling (MDS) to explore the 
relationships between the peak data from the different spectra, and to identify outlying 
spectra/patients. 
 
Non-linear adjustments  
The DXA-derived parameters of BMC and BA were strongly correlated with height 
(Paper V, Figure 2) and therefore underwent non-linear correction for height. BMD 
was not correlated with height and therefore the raw values were used in the data 
analyses. 
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Multivariate statistics 
Multivariate data analysis was performed with Matlab software on the mean intensity 
levels of the duplicate samples. Cross-validated stepwise regression was computed to 
find subsets of peaks that correlated with the delta height SDS 0–2 years, BMD, 
height adjusted BMC (BMCHA) and height adjusted bone area (BAHA). Final selection 
of reliable subsets of predictive peaks was based on a random permutation test.  
 
Between-duplicate variation 
To estimate the reliability of the peaks compared with their biological range, the ratio 
of the between-duplicate variation and the total variation was computed, giving the 
proportion of variance explained by duplicates. A low value for a certain peak meant 
that there was relatively little variation between the duplicates compared with the total 
expected biological and instrumental variation. 
 
Stepwise regression 
Subsets of peaks were selected by stepwise regression using Matlab software, for 
predicting the delta height SDS 0–2 year, BMCHA, BAHA and BMD. Sets of potential 
regression models were generated using 1 to a maximum of 15 peaks. For the 
regression analyses, either traditional stepwise regression analyses or a modified 
version of the SparseLab Matlab packages was used (158) (see Paper V for details). 
 
Random permutation tests 
Random permutation tests were performed on the stepwise regression results to test 
the stability of the results. For each number of peaks, we tested for 999 permutations 
if the permuted cross-validated R2 was equal to or above 90% of the calculated true 
cross-validated R2. In other words, we assessed if there was a significant gap (10%) 
between the calculated true cross-validated R2 and the distribution of all permuted 
cross-validated R2. Random permutation tests resulting in a p-value < 0.05 were 
considered significant.  
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RESULTS AND DISCUSSION 
Adiponectin as a marker of GH-treatment 
Growth hormone has direct effects on both longitudinal growth and adipose tissue 
(82, 160), and it has been observed that many obese children have a normal 
longitudinal growth rate in spite of very low circulating GH levels (135). This suggests 
that adipose tissue-derived factors could affect GH responsiveness, or that factors 
produced by adipose tissue, adipokines, directly effect longitudinal growth. Therefore 
we wanted to investigate adiponectin as a possible marker of GH treatment response.  
 
In this study it was found that the decrease in adiponectin correlated with growth in 
response to GH treatment after 3 months and 1 year (r = –0.38; p < 0.0001 and  
r = –0.47; p < 0.0001, respectively) (Paper I, Figure 2). Furthermore, mean serum 
adiponectin levels decreased significantly relative to baseline after the start of GH 
treatment; from 14.5 ± 5.71 to 13.1 ± 5.22 µg/mL after 1 week (p < 0.0001), to 10.3 ± 
4.82 µg/mL after 3 months (p < 0.0001), and to 12.5 ± 5.34 µg/mL after 12 months 
(p < 0.0001) (Figure 10). One-way analysis of variance of the changes in adiponectin 
levels during the first year of GH treatment also showed significant differences 
between the different time points.  
Multivariate analysis: multiple linear forward regression analysis was performed using 
SPSS (version 12.0.1, SPSS) on the auxological data and values from the protein and 
hormone analysis. The first year growth response was the dependent variable. A 
model with the following predictors was derived (beta coefficients are given in 
parentheses): the logarithmic value of GHmax during a 24 h profile (–0.429), age at the 
start of GH treatment (–0.354), GH dose (0.315), adiponectin level at baseline (0.194) 
and a constant. This model accounted for 41.6% of the variation in the growth 
response. In ANOVA analyses, the model had an F value of 15.9 and a p value of  
< 0.001. 
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Figure 10: Mean levels of serum adiponectin at the start of GH treatment and after 1 week, 3 months 
and 1 year of treatment. Values are means ± SEM. *** p < 0.0001 compared with baseline. 
 
Levels of adiponectin decreased during the first 3 months of GH treatment before 
starting to increase (Figure 10). However, adiponectin levels after 1 year of treatment 
were still significantly lower than at baseline. The finding that adiponectin levels 
decreased during GH treatment could have been related to the known association 
between increased insulin levels, lowered insulin sensitivity and decreased adiponectin 
levels (122, 130). However, no correlation between increased insulin levels and 
decreased adiponectin levels was seen in this study. 
 
It is still not known whether or not adiponectin is involved in the regulation of 
longitudinal growth, or if changes in adiponectin levels are the indirect result of the 
effects of GH on adipose tissue. However, there are data supporting the hypothesis 
that adiponectin is involved in the regulation of longitudinal growth. Firstly, 
adiponectin and its receptors are expressed in bone-forming cells (53, 155). 
Adiponectin can stimulate osteoblast proliferation and suppress osteoclasts (21, 119, 
131), and both leptin and adiponectin inhibit bone formation in vitro. The inhibitory 
effect of adiponectin on bone formation is negated by insulin (47, 155). It has also 
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been shown that children born SGA who experience catch-up growth have 
significantly lower adiponectin levels than those who do not show catch-up growth 
(36). In addition, GH treatment in children with SGA leads to lower adiponectin 
levels (36, 72, 130). Furthermore, GH exerts its lipolytic effects on adipose tissue 
through the GHR, which is expressed both in pre-adipocytes and adipocytes, and it 
has been shown that GH can stimulate pre-adipocyte proliferation and inhibit 
differentiation into adipocytes (172). Children with GHD have fewer fat cells than 
healthy children, and the cells that they do have are enlarged. After treatment with 
recombinant human GH there is an increase in the number of fat cells and a reduction 
in cell volume (30, 172). This finding suggests a direct link to adiponectin as it has 
been established that large adipocytes release less adiponectin than small adipocytes 
(37, 66). It has been speculated that the low adiponectin levels that are observed in 
obese patients, who generally have increased visceral and decreased subcutaneous fat, 
are the result of enlarged subcutaneous fat cells (161). Therefore, one would have 
expected that adiponectin levels would have increased during GH treatment as a 
direct consequence of the decreased fat mass. However, adiponectin has been shown 
to regulate GH secretion directly in in vitro studies of pituitary cells by binding to the 
adiponectin receptor (144, 159). In turn, GH can induce adiponectin receptor 2 
expression (53), whereas adiponectin decreases expression of the adiponectin receptor 
2 (31). These findings suggest the existence of a negative feedback loop between 
adiponectin and GH.  
 
Conclusion: This study showed that there was a relationship between growth 
response to GH treatment and adiponectin in short prepubertal children. It was found 
that adiponectin decreased during GH treatment and that this decrease was correlated 
with the growth response. 
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Genomics to identify novel GH- and/or IGF-I-induced genes 
(Paper II) 
To identify GH- and/or IGF-I-induced genes in a GH target tissue, primary cultured 
human chondrocytes from the growth plate were stimulated with GH and/or IGF-I 
and gene expression was analysed using Affymetrix microarray technique. 
 
In total, 25 genes were found to be regulated by GH (21 were up-regulated and 4 were 
down-regulated), 93 genes were regulated by IGF-I (72 up-regulated and 21 down-
regulated) and 11 genes were found to be regulated by both GH and IGF-I (all were 
up-regulated). These 11 up-regulated genes (Paper II, Table2,) were evaluated further. 
By combining the microarray ranking with a literature search, the COMP gene was 
identified as a candidate gene responsible for the regulation of longitudinal growth 
because of its association with conditions known to be associated with short stature 
(29, 156). Mutations in the COMP gene are associated with both 
pseudoachondroplasia and multiple epiphyseal dysplasia, both of which are 
characterized by short stature (27, 29). 
 
To verify in vivo the results of the microarray study and to assess whether COMP was 
upregulated by GH, serum COMP levels were measured by ELISA. Serum COMP 
levels increased significantly relative to baseline after the start of GH treatment; from 
1.58 ± 0.28 to 1.83 ± 0.28 µg/mL after 1 week, to 1.91 ± 0.28 µg/mL after 1 month, 
to 1.78 ±0.28 µg/mL after 3 months, and to 1.70 ± 0.24 µg/mL after 12 months 
(Figure 11). However, there was no correlation between the first year growth response 
(expressed as change in height SDS from the start of GH treatment) and COMP 
levels at any time-point. 
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Figure 11: Mean levels of serum COMP at the start of GH treatment and after 1 week, 1 month, 3 
months, and 1 year of treatment. Values are means ± SEM.*, P < 0.05, ***, P < 0.0001, compared with 
baseline. 
 
The mechanisms by which GH and IGF-I influence COMP expression and serum 
levels are unknown. Levels of COMP increased rapidly during the first month of GH 
treatment before starting to decrease progressively over time. Nevertheless, COMP 
levels after 1 year of treatment were still significantly higher than at baseline. No 
correlation was found between COMP levels in serum and the growth response. 
However, COMP may still be of importance for growth as GH treatment in children 
with pseudoachondroplasia appears to have a negative effect on growth rate (85). This 
negative effect may be caused by increased apoptosis of growth plate chondrocytes, 
that leads to a decrease in growth plate elongation (64).  
Many factors may influence the correlation between serum levels of COMP and the 
response to GH. For example, in conditions such as rheumatoid arthritis and 
osteoarthritis, increased COMP levels most likely result from the destruction of 
cartilage. In addition, COMP levels are elevated in marathon runners, suggesting that 
physical activity influences serum COMP levels in healthy subjects, possibly via the 
increase in GH secretion that occurs during or after exercise (50, 83, 124). The release 
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of COMP into the blood during certain conditions may make it hard to detect changes 
in serum levels of COMP induced by GH treatment. 
 
Conclusion: Microarray techniques could be used to identify novel GH-regulated 
genes in a GH target tissue. COMP was shown to be up regulated during GH 
treatment in short prepubertal children. 
 
Proteomics to identify novel GH responsive serum 
biomarkers (Papers III–V) 
In Papers III–V a pharmacoproteomic approach was used in order to identify novel 
GH-regulated biomarkers. SELDI-TOF-MS was used to analyse serum protein 
expression profiles during the first year of GH treatment in two different patient 
materials.  
 
At start of treatment it would be advantageous to be able to identify very poor or very 
good responders to GH treatment, because these groups require either individualized 
GH treatment in order to achieve an appropriate growth response, or do not benefit 
enough from GH treatment and should remain untreated. The goal of Paper III was 
to use proteomics to identify novel protein biomarkers that could be used to 
discriminate between good and poor responders to GH treatment.  
Overall, 82% of children with ISS (Paper III, Table 2) were correctly classified as 
having either a good or poor growth response based on changes in the intensities of 
the protein peaks, TTR and Apo A-II (13.8 kDa and 17.1 kDa, respectively) between 
baseline and 1 year on GH treatment. The 13.8 kDa peak, TTR, decreased in the high-
responder group and increased in the low-responder group, whereas the 17.1 kDa 
peak, Apo A-II, decreased in the high-responder group and remained unchanged in 
the low-responder group during 1 year of treatment (Figure 3, Paper III). 
Furthermore, it was seen that Apo A-II was associated with the GH/IGF-I axis and 
TTR was associated with the auxological axis (Paper III, Figure 2). In Table 2 (Paper 
III), it can be seen that the difference between including 2 and 15 peaks in the 
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regression models was small in terms of the change in R2. When more peaks are used, 
the lower the cross-validated R2 became. This indicated that the Apo A-II and TTR 
have the most predictive power and that including more peaks only adds noise to the 
model. 
  
In Papers IV and V serum samples from a study group of 128 children, including both 
children with ISS and GH-deficient children, from the clinical trial (TRN 98-0198-
003) were analysed to identify GH-regulated proteins that could be used to predict 
growth response and changes in bone mineralization and bone volume during GH 
treatment.  
 
In Paper IV the aim was to identify GH-regulated proteins that could be used to 
predict the 2-year growth response to GH treatment in short prepubertal children.  
For the GH-deficient group of children it was possible to predict the 2-year growth 
response at both the start and after 1 year of GH treatment (Table 3). After 1 year of 
treatment it was also possible to predict the 2-year growth response in the total group 
and in the ISS group. The majority of the proteins identified from the protein profiles 
were different apolipoproteins; Apo A-I, Apo A-II, Apo C-I and Apo C-III. Other 
proteins identified were TTR and serum amyloid A4.  
 
Conclusion: These results verified previous findings (Paper III) suggesting that Apo 
A-II and TTR may have a role in determining GH sensitivity. It was also possible to 
predict the 2-year growth response in short prepubertal children on GH treatment. 
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Table 3. The most predictive peaks identified by regression analysis at the start of GH 
treatment, and during and after 1 year of GH treatment. For each model the R2-value 
and cross-validated R2 are presented. 
 
Timepoint Group  Patients 
(n=) 
Peaks 
(n=) 
R2 CV R2 p-value Peak m/z value (kDa) 
At GH start GHD 39 7 0.73 0.61 0.032 
3.160, 3.318, 8.767 (Apo A-II), 9.135, 9.642, 
12.872 (TTR), 17.390 (Apo A-II) 
1 year GHD 39 4 0.64 0.53 0.017 
4.408 (Apo A-II), 8.696 (Apo A-II), 9.019 (Apo A-
II), 17.146 (Apo A-II) 
1 year ISS 89 8 0.47 0.35 0.015 
3.160, 4.470, 6.857 (Apo C-I), 8.767 (Apo A-II), 
8.875 (Apo A-II), 9.425 (Apo C-III), 12.607 (SAA 
4), 12.872 (TTR) 
1 year Total 128 8 0.38 0.28 0.003 
4.628, 4.470, 4.793, 8.817, 8.875, 9.019, 12.872, 
17.146 
0-1 years GHD 39 4 0.59 0.48 0.026 
4.138, 8.817 (Apo A-II), 9.019 (Apo A-II), 17.262 
(Apo A-II) 
0-1 years Total 128 8 0.35 0.24 0.003 
4.138, 8.636 (Apo A-II), 8.875 (Apo A-II), 9.135, 
9.425 (Apo C-III), 14.055 (TTR), 28.090 (Apo A-I), 
29.003  
 
Apo, apolipoprotein; CV, cross-validated; Da, Dalton; m/z, mass over charge; SAA 4, 
serum amyloid A4; TTR, transthyretin. 
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 GH has other important functions in the human body besides regulation of 
longitudinal growth. One of these functions is a role in bone mineralization. We 
therefore wanted to test the hypothesis that longitudinal growth, bone mineralization 
and ’bone volume‘ were partly regulated by different and partly by the same 
mechanism (Paper V, Figure 1).  
The same approach was used as in Paper IV to study changes in bone mineralization 
and bone volume during GH treatment. It has previously been shown that children 
with GHD and ISS have lower BMD than children in the general population and that 
GH therapy increased markers of bone formation. In this study the DXA-derived 
variables BMD, bone area and BMC were used as outcome variables. It was possible 
to predict changes in bone mineralization in terms of BMD, BMCHA and BAHA during 
the first year of GH treatment using SELDI-TOF data (Table 4). These results were 
compared to those found for longitudinal growth. From comparing the protein peaks 
included in all of the significant regression models for longitudinal growth, BMD, 
BMCHA and BAHA it was possible to conclude that there is a partial dissociation 
between mechanisms involved in longitudinal growth and bone mineralization 
because out of a total of 50 unique peaks found in the regression models, 23 were 
only present in models related to bone mineralization, and 17 peaks were only present 
in models related to height (Paper V, Table 4). As in Paper IV, the majority of the 
proteins identified from the protein profiles were different apolipoproteins; Apo A-I, 
Apo A-II, Apo C-I and Apo C-III. However, different isoforms of the proteins were 
in detected some cases. Other proteins identified were TTR, serum amyloid A4 and 
haemoglobin beta.  
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Table 4. The most predictive peaks identified from serum protein profiling by regression analysis at start 
of and during the first year of GH treatment. 
Group DXA  SELDI      
 Time 
point  
Predicted 
Variable  
Time 
point  
Peaks 
(n=) 
R2 CV 
R2 
p-value Predictors Peak m/z value (kDa) 
GHD 0 – 1 year BMD at start 5 0.64 0.52 0.038 3890I, 4156C, 7967I, 12453C, 15860I 
 0 – 2 year   5 0.64 0.48 0.018 3881I, 3890I, 4156C, 6676I (Apo C-I), 
17586C (Apo A-II) 
 
1 year BMCHA  4 0.63 0.47 0.047 4408C (Apo A-II), 6629I (Apo C-I), 
14675I, 15164C 
 2 year   3 0.61 0.52 0.017 4641I (Apo A-II), 8817C (Apo-AII), 
15363C 
 
1 year BAHA  2 0.44 0.35 0.05 6940H (Apo C-I), 15164C 
  2 year   4 0.66 0.56 0.04 6478I (Apo C-I), 6940H (Apo C-I), 
15164C, 16063C 
 
0 – 1 year BMD 0 – 1 year 3 0.61 0.51 0.047 3083I, 3890I, 12607C (SAA 4) 
 0 – 2 year   6 0.76 0.61 0.04 3160C, 3890I, 8920C (Apo A-II), 
9193I, 12607C (SAA 4), 29003C 
 
0 – 2 year BMCHA  4 0.67 0.54 0.016 8567H (Apo A-II), 9012H, 17146C 
(Apo A-II), 18030H 
ISS 0 – 2 year BAHA at start 6 0.4 0.28 0.049 2750I, 3219C, 4297I, 6629H (Apo C-
I), 7923I,12453C 
Total 0 – 1 year BAHA  10 0.42 0.29 0.008 2856I, 4297I, 7634C, 8642C (Apo A-
II), 8767C (Apo A-II), 8875C (Apo A-
II), 8920C (Apo A-II), 9012H, 12607C 
(SAA 4), 17586C (Apo A-II) 
 0 – 2 year  at start 8 0.35 0.22 0.017 3019C, 3083I, 3219C, 6629H (Apo C-
I), 8636C (Apo A-II), 8696C (Apo A-II), 
8817C (Apo A-II), 17262C (Apo A-II) 
 2 year   10 0.4 0.26 0.024 2856I, 3314H, 4466I (Apo A-II), 
7771C, 8696C (Apo A-II), 12453C, 
13890C (TTR), 17382H (Apo A-II), 
17586C (Apo A-II), 17792H (Apo A-II) 
 
BA, bone age; BMC, bone mineral content; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; 
GHD, GH-deficient; HA, height-adjusted; ISS, idiopathic short stature; CV, cross-validated. 
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To ensure that the data were valid, we tested all variables entered into the regression 
models thoroughly. When assessing the data obtained from DXA we found a clear 
relationship between height and both BMC and BA. Therefore, both of these 
variables were corrected for height (Paper V, Figure 2). 
In this study, BMCHA significantly decreased in the ISS and the total group during the 
first year of GH treatment, whereas during the second year there was a significant 
increase in BMCHA (Paper V, Table 2). After 2 years of treatment BMCHA was greater 
than at start of treatment. This is in line with ’the biphasic model‘ (103, 127) showing 
that GH initially increases bone resorption with a resultant reduction in bone,. This is 
followed by a phase of increased bone formation. After a transition point, where bone 
formation is stimulated more than bone resorption, bone mass is increased. In general, 
it will take some time for GH treatment to induce a net gain in bone mass (typically 
12–18 months in adults) as the initial deficit in bone mass must first be replaced (127). 
Alternatively, one can speculate that the process of bone tissue formation and the 
process of bone mineralization occur in parallel but at different rates (i.e. bone tissue 
formation is more rapid than bone mineralization).  
 
The results of this study supported our hypothesis that longitudinal growth, bone 
mineralization and bone volume (represented by BAHA) are partly regulated by 
different and partly by the same mechanisms. At start of treatment, regression models 
identified a number of unique protein peaks which correlated with changes in 
longitudinal growth and bone mineralization in the GH-deficient group of children. 
However, no dissociations between longitudinal growth and delta BAHA were found, 
as no significant correlations between protein peak data and bone volume were found 
in the GH-deficient group.  
A lot of the focus during the work in Papers III–IV was on developing robust 
statistical methods to ensure that the data analysed and the results presented were 
reliable. In Papers IV and V, SELDI-TOF data were analysed using multidimensional 
scaling (MDS) to explore the relationships between the protein peaks or patients. 
Three patients with outlying values were identified using this method (Figure 12). For 
these patients, several parts of the spectra deviated from the spectra for the majority 
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of patients, indicating haemolysis in the samples. This was confirmed after visual 
inspection of the protein profile and the blood sample. These spectra, from the IMAC 
30 surface, were therefore excluded from further statistical analyses (Figure 13). 
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Figure 12: Multidimensional scaling. This figure gives an example of how multidimensional scaling can 
be used to detect outlying values. In this example, the sample in the upper part of the figure from the 
patient identified as 9627 is an outlier 
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Figure 13: Haemolysis. This figure shows the serum profile from patient 9627 (upper panel) compared 
with normal serum (bottom panel). Visual inspection of the profile shows that the sample from patient 
9627 that was identified as an outlier by multidimensional scaling had in fact undergone haemolysis. 
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Conclusion: These studies demonstrated that high-throughput proteomic techniques 
can be used to identify biomarkers of growth response to GH treatment and bone 
mineralization. Of great interest was the observation that all proteins detected were 
bound to, or were part of, the HDL. The relationship between these biomarkers and 
the regulation of growth and bone mineralization is unclear. 
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GENERAL DISCUSSION 
GH action on growth in children is a complex process that depends on the interplay 
between environmental, genetic and hormonal factors, and nutrition. GH therapy 
promotes longitudinal growth and bone mineralization. The mechanisms responsible 
for the regulation of the factors involved and the interactions between the factors 
themselves are incompletely understood. There is a need to improve our 
understanding of this complex system.  
For this reason, the main aim of this thesis was to identify genes and proteins that are 
regulated by GH and may therefore be important in the regulation of longitudinal 
growth and bone mineralization in children. This will lead to better understanding of 
the molecular basis of GH action in the human body. 
To achieve this several different approaches were used. Firstly, we performed a single 
factor study (Paper I) where the relationship between adiponectin and the growth 
response was studied. Thereafter, we employed a genomic approach using a 
microarray technique to identify genes that respond to changes in GH and IGF-I in 
primary cultured human chondrocytes from the growth plate, where it is known that 
both GH and IGF-I have direct effects (Paper II). A high-throughout proteomic 
technique, SELDI-TOF, was used in Papers III–V to identify novel GH-related 
proteins in serum from short prepubertal children. Robust statistical methods were 
developed and used to ensure that proteomic data were valid and that the results were 
reliable.  
 
Methodological part 
In this thesis several different methods have been used to identify novel GH-regulated 
factors and markers. Each has its advantages and drawbacks. In Paper I, which used a 
hypothesis testing approach, a single factor study was performed using an ELISA 
technique. Using ELISA it was demonstrated that decreases in adiponectin were 
negatively correlated with the growth response. The main advantages of ELISA are; it 
is typically reproducible, easy to use and has a high throughput. The drawbacks are 
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that it is only possible to study one factor at a time using a standard ELISA, and if 
there is no commercially available assay then it is time consuming to develop a new 
one for your candidate marker.  
Papers II–V used a system biology approach to generate hypotheses. In Paper II, a 
microarray technique was used and several novel GH-regulated genes were identified. 
These observations will generate new hypothesis which need to be investigated further 
in future studies. The main advantage of using microarray is that one can quickly look 
at thousand of genes simultaneously, providing that it is possible to isolate RNA from 
the sample. Another advantage compared to many proteomic techniques is that the 
identities of almost all of the genes that can be detected are known. The main 
drawback is that the gene expression levels do not always reflect the actual levels of 
proteins in the sample studied. Microarray is also an expensive technique. Although 
the COMP was found to be upregulated in vivo, it was necessary to perform an 
ELISA study to verify the COMP gene was GH-regulated. 
 
The next step after using microarray was to study protein expression in serum using 
proteomics. Proteins secreted from many of the largest tissues and organs in the 
human body will be represented in serum. The large quantity of proteins found in 
serum, in combination with the ease of obtaining samples, makes serum one of the 
most attractive samples to study when searching for biomarkers. Papers III–V showed 
that there was great potential in using proteomic methods to identify markers of GH 
response. In Papers III–V the proteomics technique SELDI-TOF was used to identify 
novel GH-related proteins in serum from short prepubertal children.  
 
Compared to the most widely used proteomic technique two-dimensional gel 
electrophoresis (2-DE), SELDI-TOF has both advantages and disadvantages. 2-DE 
was the starting point of the proteomic era when it was invented in 1970s. 2-DE was 
the first technique that made it possible to study a large number of proteins 
simultaneously with, at the time, a high resolution. The name 2-DE originates from 
the fact that the proteins are separated into two dimensions, the first using isoelectric 
focusing and the second in terms of protein mass. 
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2-DE has evolved over time and today several thousands of proteins can be detected 
in a single serum sample (60). However, some of the spots found on the gel represent 
the same protein as do peaks in the SELDI-TOF spectra.  
 
Although 2-DE offers high resolution, its need for protein staining and subsequent 
sample handling results in limited sensitivity. Furthermore, 2-DE is highly laborious 
which makes it unsuitable for large-scale studies. There is also a limitation in that large 
or hydrophobic proteins will not enter the gel in the first dimension, and the 
technique has difficulties resolving proteins with extreme pI or low molecular weight 
(below 15 kDa) (60). 
 
Compared to 2-DE, SELDI-TOF requires small amounts of sample and is particularly 
effective in characterising both hydrophobic and low molecular weight proteins  
(< 20kDa).  
  
During the last few years, novel proteomic techniques have been developed and are 
used along side with SELDI-TOF and 2-DE. Mass spectrometry has so far mainly 
been used in studying and determining the identity of single proteins, often in 
combination with gel electrophoresis techniques like Western blot or 2-DE. However, 
the technique has rapidly evolved and today new mass spectrometry-based techniques 
using Fourier-transform mass spectrometry (FT-MS) like the Orbitrap (174) offers the 
potential to detect many proteins simultaneously from one single sample. In 
combination with extensive pre-fractionation, up to 6000 proteins can today be 
detected from one serum or plasma sample (152). The main drawbacks are the 
expensive equipment, not especially high-throughput (depending on the extensive pre-
fractionation), and last but not least, the huge amount of data generated by each run, 
which require both computer power and advanced bio-informatic tools. 
 
In Paper III, an initial pilot study in order to identify the most promising conditions 
for the identification of biomarkers was performed. Using a pilot study to find the 
optimal settings has several benefits including saving time, lowering the costs, 
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decreasing the workload and the amount of data produced. The main drawback is that 
there is a risk of missing important data because only the selected settings have been 
run due to prioritisations. There is also a risk that the study group chosen for the pilot 
study did not reflect the total study group.  
Furthermore, in this study where relatively few patients were included (n = 32) a 
problem called over-fitting can occur. This happens when a model is excessively 
complex (i.e. has too many degrees of freedom in relation to the amount of data 
available) (163). In this case, there can be too much peak data compared to the 
number of patients. Therefore, we put a lot of effort into developing and testing 
different methods in order to ensure that our results were reliable and robust.  
The first step was to test univariate analyses in the pilot study. Several protein peaks 
were identified as possible candidates that could discriminate between good and poor 
responders in terms of growth in the pilot study. However, using the total study group 
these candidates were no longer valid because of overlap between the subgroups of 
good and poor responders to GH. After searching the literature and conducting 
discussions within the group, partial least-squares regression (PLS-regression) in 
combination with cross-validated regression analyses were chosen since these methods 
were well suited for discriminant analyses and visually detected clusters of peaks giving 
the same information (Paper III, Figure 2). PLS-regression is related to the more well-
known principal component analysis (PCA). The main difference is that PLS uses a 
linear model that is projected in a plane. PLS-regression is particularly suited when the 
predictors are more than the observations, and when there is multicollinearity among 
the values (175).  
One of the main concerns was to be sure that the data analysed were reliable and of 
high quality. A lot of effort was put into finding methods that were suitable for 
detecting system biases and bad peak data. Here PCA and linear regression were 
suitable tools for identifying correlations between peak data and systematic 
parameters. Only a correlation with storage time was found, which was corrected for 
with linear regression. This shows that the SELDI-TOF system is a very stable and 
robust system and that one should avoid long-term storage of samples if at all 
possible. 
 66
  
In Papers III–IV, we put a lot of effort into the further development and testing of 
statistical methods to ensure that the data analysed were valid and the results 
presented were robust. Different approaches were used depending on the question 
asked. In Paper IV, a random permutation test was added to ensure that the results are 
true, also MDS was introduced to detect outliers. However, this procedure became 
very slow and was unpractical for data sets as large as ours, therefore, the SparseLab 
Matlab toolbox was used. The SparseLab toolbox uses different kinds of regression 
analyses and is very fast compared with the previous analyses without losing accuracy. 
In comparison to the analyses performed in Paper IV which took several hours, the 
analyses in Paper V only took a few minutes.  
 
Paper V used DXA which is the most widely used technique for bone measurements. 
BMC, BA and BMD can be determined. Bone volume is not available from DXA 
measurements and therefore height adjusted BA (BAHA) was used as a proxy measure 
of bone volume in this study. In growing children, BMC, BMD and BA are closely 
related to age and bone maturation (15) and BMD can be falsely low in short children 
due to short bones and falsely high in tall children because of longer bones (125). In 
Paper V, strong correlations were found between height and both BMC and BA and 
therefore these data was corrected for height. In this study, there was no correlation 
between BMD and height, most likely because BMD is in a way already corrected for 
height (BMC/BA), whereas BA depends on the length of the bones. It is also 
important to bear in mind that BMD gives an areal density (BMDarea) and not a 
measure of true bone density (15). Volumetric BMD is a function of BMC per volume 
of bone. This can not be measured with DXA; peripheral quantitative computed 
tomography (pQCT) or magnetic resonance imaging (MRI) have to be used. 
However, approximations have been done for lumbar trabecular bone (98). In this 
study, height was a more suitable way to correct the BMA and BA than age. This was 
most likely because the children were small for their age and, therefore, if the data 
should have been corrected for age, bone age should probably have been more 
appropriate to correct for than biological age. This has previously been shown in 
prepubertal children with chronic renal insufficiency (102). BMD of these patients was 
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low at baseline when compared with healthy age-matched controls, but normal when 
compared with height- and bone-age-matched controls.  
Using SELDI-TOF to study changes in bone mineralization is just one part of the 
puzzle in understanding the complex regulation of bone mineralization, as the 
mineralization process is governed by multiple factors that interplay with each other, 
for instance the availability of vitamin D, calcium and a number of limiting proteins.  
 
The main advantages of proteomics techniques like SELDI-TOF are that they are 
high throughput and study the active products of the genes. A drawback is that the 
identities of the proteins are not available and other techniques have to be used to be 
able to identify the proteins of interest. For SELDI-TOF and other proteomic 
techniques a major limitation is that many samples, like serum, is so complex that no 
technique can identify every protein in the samples and compromises have to be 
made. One of the challenges in proteomic analyses of serum is the broad range of 
expression levels between proteins with low and high abundance (12, 40, 164). In 
order to partly overcome this problem, we used fractionated serum that was analysed 
on different array surfaces in order to detect proteins in a larger area of the proteome. 
Alternative strategies are to use antibodies or different bead-based techniques, such as 
the Proteominer (Bio-Rad), to deplete the most abundant proteins. In the work of 
discovering protein biomarkers relevant to a condition or disease one would like to 
study the actual tissue instead of serum. However, it is often very difficult to get 
samples from the actual tissue, especially in children. 
 
Physiological part 
In the studies included in this thesis, HDL-related proteins were found to be markers 
of GH action. Not much is known about the relationship between GH and the HDL-
related biomarkers found in Papers III–V; the apolipoproteins, TTR, SAA 4 and 
haemoglobin beta. There are contradictory results regarding the effects of GH 
treatment given as daily subcutaneous injections on the HDL (71, 100, 104).  
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From these studies, it is not possible to draw any conclusions whether the markers 
identified are actually involved in the regulation of longitudinal growth or if they are 
indirect markers of the effects of GH on the target tissues. Interpretation of the 
results is also complicated by the findings of different regulated isoforms and cleavage 
products of Apo A-II as seen if Figures 1, 2 and 3 in Paper IV. The physiology behind 
this will be an interesting topic to evaluate further in future studies. The functions of 
the different isoforms and interpretation of having found these is not clear. However, 
it is easy to speculate that different isoforms have different biological functions as 
seen for GH (18, 112, 146). 
 
In the field of GH research, proteomics has not been used frequently. In a small study 
of healthy adults with GHD, SELDI-TOF was used and it was found that 
haemoglobin alpha-chain was up-regulated during GH treatment (34). In a later study 
by the same group, IGF-I was found to be up-regulated (33). The same group have 
also shown that the pro-inflammatory calgranulins were down-regulated in response 
to GH treatment, and were therefore proposed to be markers of GH action (35). 
Using 2-DE in combination with MS/MS, preliminary results indicated that isoforms 
of transthyretin, clusterin, Apo E and Apo-AI were differentially expressed during 
GH treatment and may be potential biomarkers for initiating studies using 
recombinant human GH (45) This is in line with our findings that TTR and Apo AI 
are regulated during GH treatment.  
 
The importance of identification of novel GH-regulated 
factors  
Detailed understanding of the molecular mechanisms behind growth failure and GH 
action in its target tissues opens possibilities for the development of better diagnostic 
tools and improved selection criteria for drug treatment. It is also possible to develop 
better prediction models for longitudinal growth, which lead to treatment with 
individualized GH dosages with positive impact on the child and gives economical 
benefits for public medical services. Furthermore, it may contribute to the 
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identification of some causes of growth failure in the selected groups of children and 
increase the possibility to monitor the progression of GH treatment and to evaluate 
the efficiency of the GH treatment.  
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CONCLUSIONS 
The main aim of the studies included in the thesis was to identify novel GH-
responsive genes and proteins of importance for the regulation of longitudinal growth 
and bone mineralization in children.  
To achieve these goals several different approaches were successfully used; including 
traditional methods such as ELISA and cell culture experiments in combination with 
genomic and proteomic techniques. Using and developing robust statistical methods 
were a prerequisite to ensure that proteomic data were valid and that the results were 
reliable.  
 
I. There is a relationship between growth response to GH treatment and adiponectin 
in short prepubertal children. It was found that adiponectin decreases during GH 
treatment and that the decrease is correlated with the growth response. 
II. A genomic approach can be used to identify novel GH-regulated genes in a GH 
target tissue. COMP was found to be up-regulated during GH treatment in short 
prepubertal children using ELISA. 
III. A pharmacoproteomic approach can be used to identify protein biomarkers of 
growth response to GH treatment and bone mineralization. All biomarkers detected 
except for haemoglobin beta are bound to, or are part of, the HDL.  
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FUTURE PERSPECTIVES  
These studies show that there is great potential in using proteomics, genomics and 
system biology studies in general, in the GH research area. Further characterization 
and evaluation of the biomarkers of GH response that were identified will improve 
knowledge about the mechanism(s) involved in the regulation of the growth response. 
It is hoped that in the future these data will be incorporated within prediction models 
for longitudinal growth that will also include targets related to gaining optimal bone 
quality and metabolism. Protein peak data could be used to replace missing pre-
treatment data that is included in current prediction models. Using proteomic data to 
predict changes in bone quality may help to determine when it is appropriate to 
discontinue GH treatment after final height in order to ensure that peak bone mass 
has been reached. 
The use of system biology, which is a hypothesis generating approach, will increase in 
the research on multifactorial diseases in general, as well as in the GH research field. 
Different types of protein arrays, where large-scale studies of protein–protein 
interactions, transcription factors and enzymes can be studied, will be used more 
extensively in the future. In general, system biology generates a lot of candidate 
biomarkers leading to an increasing need for techniques that can be used to verify the 
findings as knock-out animal experiments and short interference RNA studies there 
genes (typically) in cell cultures are silenced. These techniques can be used to study 
direct effects of GH on its target tissues. It would also be of great interest to use a 
system biology approach in combination with microdialysis in GH target tissues to 
study the local GH response. 
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